On October 2, 2024, two travelers in Hamburg, Germany were hospitalized due to displaying symptoms consistent with Marburg virus. The two travelers had recently arrived from Rwanda, a country that is currently experiencing an outbreak of the disease, and one of them had reportedly come into contact with someone later confirmed to be infected with Marburg virus. Rwanda has had a total of 26 confirmed cases of Marburg virus, with eight deaths. The World Health Organization (WHO) has assessed the risk as very high for Rwanda and high at the regional level. Currently, there are no approved vaccines or therapies for Marburg virus. However, Soligenix, Inc. (SNGX) is developing a vaccine for Marburg virus (MarVax ) based on the company's proprietary ThermoVax technology. It showed 100% protection in non-human primates and exhibits stability for at least two years at 40 C.
